Ralph H. Johnson VA Medical Center

Ralph H. Johnson VA Medical Center
109 Bee Street
Charleston, SC 29401

Shannon Elam, RN, Research Coordinator: shannon.elam@va.gov
Kathy Jeter, RN, Research Coordinator: katherine.jeter2@va.gov
Nicky Thornley, Research Coordinator: nicola.thornley@va.gov

National Cancer Institute Community Oncology Research Program logo

As an affiliate of the Medical University of South Carolina, Ralph H. Johnson VA Medical Center is an active Minority/Underserved NCORP site. Ralph H. Johnson VA Medical Center is currently active on the following clinical trials addressing various cancer types. Ask your health care provider for more information.

Bone Marrow Transplant

  • S1803: Testing the addition of a new drug, daratumumab/rHuPH20, to the usual treatment (lenalidomide) as post-stem cell transplant treatment for multiple myeloma
    This phase III trial compares the effect of usual treatment (lenalidomide) to using daratumumab/rHuPH20 plus the usual treatment after stem cell transplantation in patients with multiple myeloma.
    Trial Details 


  • A021806: Testing the use of the usual chemotherapy before and after surgery for removable pancreatic cancer
    This trials compares perioperative chemotherapy (given around the time of surgery) to adjuvant chemotherapy (given after surgery) for treatment of pancreatic cancer that can be removed by surgery.
    Trial Details
  • CC005: A study to examine how often (every 5 years or 10 years) a colonoscopy should be done in participants who had one or two small growths of tissue removed from their colon
    This trial compares how often (every 5 of 10 years versus every 10 years) a colonoscopy should be done in participants who had one or two non-cancerous polyps removed from their colon.
    Trial Details


  • A031803: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
    This trial studies the effect of adding the immunotherapy drug pembrolizumab to gemcitabine for patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment.
    Trial Details
  • EA8184: To Evaluate if Green Tea can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring (Pending Activation)
    This trial studies whether green tea catechins can prevent progression of prostate cancer from a low-risk stage to a higher-risk stage in men on active surveillance.
    Trial Details

Malignant Hematology

  • EAA181: Testing the use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma
    This trial compares the combination of four drugs (daratumumab-hyaluronidase, bortezomib, lenalidomide and dexamethasone) to a three-drug combination (daratumumab-hyaluronidase, lenalidomide and dexamethasone) in patients with newly diagnosed multiple myeloma.
    Trial Details
  • NHLBI-MDS: Protocol for the collection of information and samples to be used in the study of MDS
    The purpose of this trial is to collect blood, bone marrow, other tissues (hair follicles), cells from the inside of the cheek, and information from patients to investigate how this disease changes over time.
    Trial Details


  • LungMAP: Targeted Treatment for Advanced Non-Small Cell Lung Cancer
    This trial will test patient specimens to determine eligibility in biomarker-driven and non-matched substudies included within the LungMAP umbrella protocol.
    Trial Details
  • S1900E: Testing the Use of Targeted Treatment for KRAS G12C Mutated Advanced Non-Squamous Non-Small Cell Lung Cancer (LungMAP Sub-Study)
    This treatment trial will study the effect of AMG510 in treating non-squamous non-small cell lung cancer that is stage IV or has recurred and has a specific KRAS gene mutation.
    Trial Details
  • S1900F: A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib (LY3527723) In Patients With Non Squamous RET Positive Stage IV Non Small Cell Lung Cancer and Progression of Disease On Prior RET Directed Therapy (LungMAP Sub-Study)
    This phase II LungMAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy.
    Trial Details
  • S1800D: Testing the Use of Combination Immunotherapy Treatment (N-803 (ALT-803) plus Pembrolizumab) against the Usual Treatment for Advanced Non-Small Cell Lung Cancer (LungMAP Non-Match Sub-Study)
    This trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other parts of the body.
    Trial Details